Core Viewpoint - Yuaneng Bio has officially launched its Series B financing and is actively preparing for its listing on the Sci-Tech Innovation Board, focusing on the automation of low-temperature storage technology in the biopharmaceutical sector [1][6]. Group 1: Company Overview - Yuaneng Bio has been dedicated to the research and development of advanced automated low-temperature storage equipment for nearly eight years, with an investment of approximately 800 million yuan [3][6]. - The company has applied for over 600 domestic and international patents, with more than 500 granted [1][3]. - The company aims to transform low-temperature storage technology from laboratory applications to industrialization, driven by policy, capital, and entrepreneurial efforts [1][6]. Group 2: Product Development - Yuaneng Bio has developed a series of automated deep low-temperature biological sample storage products, including the BSN, P, AM, IVF, PBM, and BSE series [3][4]. - The company has achieved breakthroughs in technology, such as the innovative "honeycomb" storage structure that prevents cross-contamination and maintains a stable low-oxygen, frost-free environment [3][4]. - The Orcella duo1100S automated deep low-temperature storage system won the "2025 Outstanding New Product Award" at the ISBER awards in Canada [4]. Group 3: Market Strategy - The company is focusing on standardizing and modularizing its products to facilitate future mass production and reduce costs [4][6]. - Yuaneng Bio is expanding its market presence domestically while also strengthening collaborations with global partners to reach overseas customers [4][6]. - The company is targeting various application scenarios, including hospitals, disease control centers, biopharmaceutical companies, and animal research centers, as well as exploring the potential of home-based cell storage solutions [6][7]. Group 4: Future Plans - Yuaneng Bio is set to complete the construction of a smart manufacturing base in Shanghai in 2024, covering nearly 10,000 square meters [6]. - Following a successful Series A financing of 410 million yuan in 2022, the company is now preparing for its Series B financing and plans to list on the Sci-Tech Innovation Board [6][7]. - The primary use of future funds will be for factory construction and to promote the mass production of low-temperature storage equipment [6].

Core Insights - The company, Yuan Neng Biological, focuses on advanced automated low-temperature storage equipment for biological samples, addressing pain points in the biopharmaceutical industry [1][2] - The company has developed innovative technologies, including a "honeycomb" storage structure to eliminate cross-contamination risks and a vacuum negative pressure system for precise sample handling [2] - Yuan Neng Biological has received recognition for its products, including the "Outstanding New Product Award" at the ISBER awards and inclusion in the National High-Quality Medical Device Export Selection Guide [1][2] Company Developments - Yuan Neng Biological has applied for over 600 patents domestically and internationally, with more than 500 granted, and its products are now serving both domestic and international markets, including the US and Japan [2] - The company is initiating a Series B financing round in 2025 and preparing for an independent listing, following a successful A round financing of 410 million yuan in 2022 [3] - The company envisions a trillion-yuan market for cell storage, aiming to make cell storage a common practice for families, starting from the storage of umbilical cords at birth [3] Technological Innovations - The company has integrated 5G IoT and AI technologies into its automated sample storage systems, creating a smart, traceable ecosystem for biological sample management [2] - Innovations include a modular "C-type structure" for efficient sample transport and a stable, frost-free environment for sample preservation [2] Market Outlook - The company believes that as cell technology becomes more widespread, the vision of a world with no diseases will become more attainable [3] - The cell storage market is expected to grow significantly, with the potential for prices to become more accessible as the industry scales [3]